Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Dalesio, 1983, Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Group, J Urol, 129, 730, 10.1016/S0022-5347(17)52330-7
Parmar, 1989, Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party), J Urol, 142, 284, 10.1016/S0022-5347(17)38731-1
Herr, 1989, Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression, J Urol, 141, 22, 10.1016/S0022-5347(17)40575-1
Kiemeney, 1993, Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer, J Urol, 150, 60, 10.1016/S0022-5347(17)35397-1
Kurth, 1995, Factors affecting recurrence and progression in superficial bladder tumors, Eur J Cancer, 31A, 1840, 10.1016/0959-8049(95)00287-S
Allard, 1998, The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index, Br J Urol, 81, 692, 10.1046/j.1464-410x.1998.00628.x
Millan-Rodriguez, 2000, Multivariate analysis of the prognostic factors of primary superficial bladder cancer, J Urol, 163, 73, 10.1016/S0022-5347(05)67975-X
Millan-Rodriguez, 2000, Primary superficial bladder cancer risk groups according to progression, mortality and recurrence, J Urol, 164, 680, 10.1016/S0022-5347(05)67280-1
Solsona, 2000, The 3 month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer, J Urol, 164, 685, 10.1016/S0022-5347(05)67281-3
Kaasinen, 2002, Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma, Eur Urol, 42, 167, 10.1016/S0302-2838(02)00260-9
Kwak, 2004, Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer, J Urol, 171, 149, 10.1097/01.ju.0000099825.98542.a8
Shariat, 2005, Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder, J Urol, 173, 1518, 10.1097/01.ju.0000154696.48217.75
Newling, 1995, Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer, Eur Urol, 27, 110, 10.1159/000475139
Bouffioux, 1992, Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin, J Urol, 148, 297, 10.1016/S0022-5347(17)36577-1
Kurth, 1997, Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone, J Urol, 158, 378, 10.1016/S0022-5347(01)64484-7
Witjes, 1998, Long-term follow-up of an EORTC randomized prospective trial comparing intravesicalbacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer, Urol, 52, 403, 10.1016/S0090-4295(98)00212-X
Van der Meijden, 2000, The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials, J Urol, 164, 1533, 10.1016/S0022-5347(05)67022-X
Caplan, 1994, Analysis of the probability and risk of cause-specific failure, Int J Radiation Oncology Biol Phys, 29, 1183, 10.1016/0360-3016(94)90416-2
Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Statist Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
Gattegno, 2004, T1G3 bladder cancer: conservative management or cystectomy?, Eur Urol, 45, 399, 10.1016/j.eururo.2003.11.027
Turner, 2004, T1G3 bladder tumors: the case for conservative treatment, Eur Urol, 45, 401, 10.1016/j.eururo.2003.11.008
Malavaud, 2004, T1G3 bladder tumors: the case for radical cystectomy, Eur Urol, 45, 406, 10.1016/j.eururo.2003.11.007
Manoharan, 2005, Optimal management of the T1G3 bladder cancer, Urol Clin N Am, 32, 133, 10.1016/j.ucl.2005.02.002
Thalmann, 2004, Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?, J Urol, 172, 70, 10.1097/01.ju.0000132129.87598.3b
Shahin, 2003, A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival, J Urol, 169, 96, 10.1016/S0022-5347(05)64044-X
Patard, 2002, Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumors, Eur Urol, 41, 635, 10.1016/S0302-2838(02)00173-2
Serretta, 2004, TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years, Eur Urol, 45, 730, 10.1016/j.eururo.2003.12.002
Orsola, 2005, Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG treated and BCG non-treated patients, Eur Urol, 48, 231, 10.1016/j.eururo.2005.04.013
Schrier, 2004, Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy, Eur Urol, 45, 292, 10.1016/j.eururo.2003.10.006
Bernardini, 2001, The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma, J Urol, 165, 42, 10.1097/00005392-200101000-00011
Fujii, 1998, Significance of bladder neck involvement on progression in superficial bladder cancer, Eur Urol, 33, 464, 10.1159/000019636
Lee, 2005, Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer, J Urol, 173, 246, 10.1016/S0022-5347(18)35067-5
Kamat, 2005, The case for early cystectomy in non muscle-invasive micropapillary transitional cell carcinoma of the bladder, J Urol, 173, 247, 10.1016/S0022-5347(18)35071-7
Kausch, 2002, Molecular aspects of bladder cancer: III. Prognostic markers of bladder cancer, Eur Urol, 41, 15, 10.1016/S0302-2838(01)00007-0
Schmitz-Drager, 2000, p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?, Eur Urol, 38, 691, 10.1159/000020364
Kim, 2002, Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer, Urol, 60, 816, 10.1016/S0090-4295(02)01909-X
Moore, 2005, Expression of cyclooxygenase-2 is associated with stage, grade and recurrence-free survival in superficial bladder cancer, J Urol, 173, 248, 10.1016/S0022-5347(18)35075-4
Pawinski, 1996, A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer, J Urol, 156, 1934, 10.1016/S0022-5347(01)65396-5
Sylvester, 2004, A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of publishes results of randomized clinical trials, J Urol, 171, 2186, 10.1097/01.ju.0000125486.92260.b2
Jakse, 2004, A second-look TUR in T1 transitional cell carcinoma: Why?, Eur Urol, 45, 539, 10.1016/j.eururo.2003.12.016
Bohle, 2003, Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity, J Urol, 169, 90, 10.1016/S0022-5347(05)64043-8
Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5
Andius, 2004, Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression, BJU Int, 93, 980, 10.1111/j.1464-410X.2003.04764.x
Saint, 2003, Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature, Eur Urol, 43, 351, 10.1016/S0302-2838(03)00048-4
Davis, 2002, Superficial bladder carcinoma treated with bacillus Calmette-Guerin: Progression-free disease specific survival with minimum 1-year follow-up, J Urol, 167, 494, 10.1016/S0022-5347(01)69072-4
Griffiths, 2002, Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance, J Urol, 167, 2408, 10.1016/S0022-5347(05)64994-4
Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5